FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biochemistry. The invention also involves using antibodies for treating or preventing IL-4 and (or) IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
EFFECT: humanised anti-IL-4 and anti-IL-13 antibodies and their fragments, which specifically bind to IL-4 and IL-13 are presented.
32 cl, 2 dwg, 8 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
MONOCLONAL ANTIBODY TO IL-5RΑ | 2017 |
|
RU2698048C2 |
ANTI-IL-17F ANTIBODIES AND METHODS FOR USE THEREOF | 2010 |
|
RU2605318C2 |
ANTIBODIES BINDING IL-4 AND/OR IL-13, AND THEIR USE | 2015 |
|
RU2721236C2 |
ANTI-IL-22R-ANTIBODIES | 2017 |
|
RU2758721C2 |
HUMAN ANTIBODIES TO IL-β1 | 2001 |
|
RU2286351C2 |
IL-17 ANTAGONIST ANTIBODIES | 2005 |
|
RU2426741C2 |
ANTIBODIES OF HIGH AFFINITY TO IL-6-RECEPTOR OF HUMANS | 2007 |
|
RU2433138C2 |
HUMANISED ANTI-IL-10 ANTIBODIES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | 2010 |
|
RU2587622C2 |
METHOD FOR OBTAINING BI-SPECIFIC ANTIBODIES, BI-SPECIFIC ANTIBODIES AND THERAPEUTIC APPLICATION OF SUCH ANTIBODIES | 2018 |
|
RU2795240C2 |
ANTIBODIES BINDING IL-4 AND/OR IL-13, AND USE THEREOF | 2015 |
|
RU2705551C2 |
Authors
Dates
2016-04-10—Published
2008-10-14—Filed